中成药
中成藥
중성약
CHINESE TRADITIONAL PATENT MEDICINE
2010年
3期
366-369
,共4页
魏思忱%郑国启%孔郁%田树英%张秀刚%宋慧
魏思忱%鄭國啟%孔鬱%田樹英%張秀剛%宋慧
위사침%정국계%공욱%전수영%장수강%송혜
谷参肠安胶囊%溃疡性结肠炎%IL-10%IL-18
穀參腸安膠囊%潰瘍性結腸炎%IL-10%IL-18
곡삼장안효낭%궤양성결장염%IL-10%IL-18
Compound Glutamine Entero-soluble Capsule%ulcerative colitis%IL-10 and IL-18
目的:探讨谷参肠安胶囊(L-谷氨酰胺、甘草、茯苓和白术)治疗活动期溃疡性结肠炎(UC)的疗效及对细胞因子的影响.方法:活动期UC患者82例,随机分为两组,埘照组(39例)口服柳氮磺胺吡啶(或美沙拉嗪),同时用琥珀酸氧化考的松及庆大霉素、蒙脱石散保留灌肠,治疗组(43例)在上述治疗基础上,口服谷参肠安胶囊.治疗2个月后评价两组疗效以及患者血中细胞因子IL-10和IL-18的变化.结果:治疗后两组临床表现总评分明显下降,且治疗组优于对照组,两组比较筹异有统计学意义(P<0.05).两组治疗后结肠镜表现均有改善,治疗组优于对照组;疾病活动指数(DAI)降低(P<0.05),降低幅度治疗组优于对照组(P<0.05).两组均未见明显的不良反应.治疗后细胞因子IL-10的水平升高,且治疗组优于对照组,而IL-18虽有降低,但两组间无统计学差异.结论:谷参肠安口服辅助治疗活动期UC近期疗效明显.
目的:探討穀參腸安膠囊(L-穀氨酰胺、甘草、茯苓和白術)治療活動期潰瘍性結腸炎(UC)的療效及對細胞因子的影響.方法:活動期UC患者82例,隨機分為兩組,塒照組(39例)口服柳氮磺胺吡啶(或美沙拉嗪),同時用琥珀痠氧化攷的鬆及慶大黴素、矇脫石散保留灌腸,治療組(43例)在上述治療基礎上,口服穀參腸安膠囊.治療2箇月後評價兩組療效以及患者血中細胞因子IL-10和IL-18的變化.結果:治療後兩組臨床錶現總評分明顯下降,且治療組優于對照組,兩組比較籌異有統計學意義(P<0.05).兩組治療後結腸鏡錶現均有改善,治療組優于對照組;疾病活動指數(DAI)降低(P<0.05),降低幅度治療組優于對照組(P<0.05).兩組均未見明顯的不良反應.治療後細胞因子IL-10的水平升高,且治療組優于對照組,而IL-18雖有降低,但兩組間無統計學差異.結論:穀參腸安口服輔助治療活動期UC近期療效明顯.
목적:탐토곡삼장안효낭(L-곡안선알、감초、복령화백술)치료활동기궤양성결장염(UC)적료효급대세포인자적영향.방법:활동기UC환자82례,수궤분위량조,시조조(39례)구복류담광알필정(혹미사랍진),동시용호박산양화고적송급경대매소、몽탈석산보류관장,치료조(43례)재상술치료기출상,구복곡삼장안효낭.치료2개월후평개량조료효이급환자혈중세포인자IL-10화IL-18적변화.결과:치료후량조림상표현총평분명현하강,차치료조우우대조조,량조비교주이유통계학의의(P<0.05).량조치료후결장경표현균유개선,치료조우우대조조;질병활동지수(DAI)강저(P<0.05),강저폭도치료조우우대조조(P<0.05).량조균미견명현적불량반응.치료후세포인자IL-10적수평승고,차치료조우우대조조,이IL-18수유강저,단량조간무통계학차이.결론:곡삼장안구복보조치료활동기UC근기료효명현.
AIM:To observe the therapeutic effect of Compound Glutamine Entero-soluble Capsule(CGC)(L-
glutamin,Radix et Rhezoma glycyrrhizae,Poria and Rhizoma atractylodis macrocephalae)on active ulcerative coli
tis(UC)and to investigate its influence on the cytokines.METHODS:Eighty-two patients with active UC were
randomly assigned to the treatment group(43 patients)and the control group(39 patients).Patients in two groups
received the basic treatment with salicylazosulfapyridine or mesalazine by month and retention enema(hydrcortisone
sodium succinate,Gentamicin,and Smectite Powder),the patients in treatment group with the addition of CGC.
The efficacy,such as the clinical symptom score,colon mucosa inflammation and the changes of IL-10 and IL-18 in
serum 2 months after treatment were evaluated.RESULTS:Two months after treatment,the clinical symptom
score and colon mucosa inflammation decreased significantly,especially in the treatment group(P<0.05).The
decrease of disease active index in the treatment group was superior to those in the control group(P<0.05).The
average serum level of IL-10 significantly increased,especially in the treatment group(P<0.05).The average se
rum level of IL-18 was low,but no statistic difference in two groups.No adverse reaction was found in all patients.
CONCLUSION:Compound Glutamine Entero-soluble Capsule shows supportive treatment effect on active ulcera
tive colitis.